论文部分内容阅读
目的探讨培美曲塞联合顺铂与吉西他滨联合顺铂两种治疗方案治疗晚期非小细胞肺癌(NSCLC)患者的疗效及对肿瘤标志物水平的影响。方法选取2013年5月至2016年7月间上海市第六人民医院收治的128例NSCLC患者,根据治疗方法将入选患者分为观察组与对照组,每组64例。观察组患者采用培美曲塞联合顺铂进行治疗,对照组患者采用吉西他滨联合顺铂进行治疗。比较两组患者的治疗总有效率、临床症状改善情况及治疗前后肿瘤标志物水平变化情况。结果观察组患者治疗总有效率为96.9%,显著高于对照组患者的79.7%。两组比较,差异有统计学意义(P<0.01)。观察组患者咳嗽、咳痰、发热、胸痛、乏力和气促的发生率均低于对照组患者,差异均有统计学意义(均P<0.05)。治疗后观察组患者的肿瘤标记物均显著低于对照组患者,差异均有统计学意义(均P<0.05)。结论培美曲塞联合顺铂治疗晚期NSCLC患者疗效较为显著,改善了肿瘤标志物水平,值得推广。
Objective To investigate the efficacy of pemetrexed combined with cisplatin and gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC) and its effect on tumor markers. Methods A total of 128 patients with NSCLC admitted to Shanghai Sixth People’s Hospital from May 2013 to July 2016 were selected and divided into observation group and control group according to the treatment method, with 64 cases in each group. Patients in the observation group were treated with pemetrexed combined with cisplatin, and patients in the control group were treated with gemcitabine plus cisplatin. The total effective rate, the improvement of clinical symptoms and the changes of tumor markers before and after treatment were compared between the two groups. Results The total effective rate of observation group was 96.9%, significantly higher than that of the control group 79.7%. The difference between the two groups was statistically significant (P <0.01). The incidence of cough, sputum, fever, chest pain, fatigue and shortness of breath in the observation group were lower than those in the control group (all P <0.05). After treatment, the tumor markers in the observation group were significantly lower than those in the control group, the differences were statistically significant (P <0.05). Conclusion Pemetrexed combined with cisplatin in the treatment of advanced NSCLC patients with more significant effect, improve the level of tumor markers, it is worth promoting.